One of the microcap pharma stocks specializes in the research, development, manufacturing, and distribution of high-quality pharmaceutical products, including B-lactam antibiotics and antiretroviral drugs. The stock has jumped to its 5 percent upper circuit after securing an order worth approx. Rs. 232 crore for the supply of high-demand pharmaceutical products.
Stock Price Movement
With a market capitalization of Rs. 895.96 crores, the shares of Bharat Parenterals Limited’s stock surged up to 5 percent, reaching near the upper circuit of Rs. 1,337.65 per share on Wednesday, up from its previous closing price of Rs. 1,274 per share.
What Happened
Bharat Parenterals Limited (BPL) has announced the receipt of an order worth $27 million (approximately Rs. 232 crores) for the supply of high-demand pharmaceutical products over the next 18-24 months. This is the largest order the company has ever secured, marking a key milestone in its growth.
The company is based in Vadodara, Gujarat. It is a leading manufacturer of injectable pharmaceutical formulations and is committed to delivering affordable, high-quality healthcare solutions globally. The company’s strong production capacities and extensive portfolio in the injectables segment reinforce its leadership in the global pharmaceutical market.
Also read…..
Products and Services
The company provides a variety of healthcare products, including B-lactam antibiotics, antiretroviral drugs, cephalosporins, tablets, capsules, liquid orals, ointments, creams, and powdered injections, covering multiple therapeutic areas for effective treatment and care.
Recent quarter results
Bharat Parenterals Limited’s revenue has increased from Rs. 60 crore in Q2 FY24 to Rs. 72 crore in Q2 FY25, which has grown by 249.33 percent. The company has turned its net profit into negative, from Rs. 2 crore in Q2 FY24 to Rs. -18 crore in Q2 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
